Clinical trials: Terminal Malignant Tumors
Lymphoma, Non-Hodgkin, Neoplasms
Meaning-Centered Psychotherapy in Advanced Cancer
We have developed an 8-week Meaning-Centered Group Psychotherapy designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose despite the limitations of their cancer illness.
- Trial name
- NCT00067288
- Testing
- Meaning-Centered Group Psychotherapy, Standard Supportive Group Psychotherapy
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Refractory Solid Tumor
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
Increased fibroblast activation protein expression is positively correlated with the aggressiveness of cancer. Radiolabeled fibroblast activation protein inhibitor therapy, also known as radioligand therapy has become a novel…
- Trial name
- NCT05963386
- Testing
- 177Lu-DOTA-EB-FAPI radionuclide therapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Measuring the Impact of MANNA s Medically Tailored Meal Program in Patients With a Non-terminal Cancer Diagnosis
This study identifies patient-important outcome measures and develops a survey that assesses the impact of nutritional interventions among cancer patients.
- Trial name
- NCT05118802
- Testing
- Interview, Survey Administration
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Solid Tumors, Adult
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
- Trial name
- NCT04587479
- Testing
- JAB-8263
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma
This research study is studying biomarkers in tumor tissue samples from young patients with neuroblastoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors identify biomarkers and learn more…
- Conditions
- Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma
- Trial name
- NCT01358617
- Testing
- diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Children's Oncology Group
NSCLC, SCLC
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.
- Conditions
- NSCLC, SCLC, CRPC, ESCC
- Trial name
- NCT04686682
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell
Project to Improve Communication About Serious Illness - Pilot Study
This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about…
- Conditions
- Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure
- Trial name
- PICSI-P (NCT03746392)
- Testing
- Jumpstart Intervention
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Washington
Advanced Tumors
Study of BMS-986158 in Subjects With Select Advanced Cancers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
- Trial name
- BET (NCT02419417)
- Testing
- BMS-986158, Nivolumab
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Neuroendocrine Tumors
The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET
"The patient's journey" is an interview based study assessing the patients' experience from the first symptoms to a final diagnosis focusing on patients with small intestinal neuroendocrine tumors.
- Trial name
- NCT03840720
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Vastra Gotaland Region
Neuroblastoma
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00417053
- Testing
- filgrastim, busulfan, carboplatin
- Sponsor
- Children's Cancer and Leukaemia Group
Breast Cancer, Pancreatic Cancer
OMT-111 for Terminal Stage Solid Tumors
Patients with terminal stage of metastatic non-small cell lung cancer, metastatic triple negative breast cancer, or advanced or metastatic pancreatic adenocarcinoma resisting to standard therapies.
- Conditions
- Breast Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04520386
- Testing
- OMT-111
- Where
- 2 sites in Vietnam
- Volunteers
- 78 people
- Sponsor
- MetiMedi Pharmaceuticals
Pediatric Brain Tumor
Compassionate Treatment in Children With Brain Tumors With the Cytotron®
This is a prospective case-control study. This study is expected to last for approximately 12 months, comprised of 4-8 weeks of enrollment period, 28 days of treatment and 6 months of follow up.
- Trial name
- NCT03577600
- Testing
- QMRT with the Cytotron®
- Where
- Mexico
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Palliative Patients, Terminal Malignant Tumors
Effect of Breathing Exercises on Pain, Dyspnea, and Function in Terminal-Stage Cancer Patients
This study aims to evaluate the effects of supervised breathing exercises on pain, dyspnea, and functionality in terminal-stage cancer patients receiving palliative care.
- Conditions
- Palliative Patients, Terminal Malignant Tumors, Breathing Techniques
- Trial name
- NCT07164352
- Testing
- Breathing Exercises, Informational Brochure
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people
- Sponsor
- Atlas University
Glioblastoma Multiforme
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure. The first phase of the study (dose escalation) will determine the maximum tolerated dose (MTD).
- Trial name
- NCT02296476
- Testing
- Birabresib
- Volunteers
- 12 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pleural Effusion, Heart Failure
Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)
To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).
- Conditions
- Pleural Effusion, Heart Failure, Malignant Neoplasm, Fluid Overload
- Trial name
- NCT05797649
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- Chinese University of Hong Kong
Advanced Cancer, Terminal Malignant Tumors
Nurses' Competence and Role in Survival Prediction and Prognostic Communication
[Background] Nurses' roles in survival prediction and prognostic communication have historically been limited due to role delineation, lack of formal training, and cultural norms.
- Conditions
- Advanced Cancer, Terminal Malignant Tumors, Hospices
- Trial name
- NCT06962553
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Peripheral Nerve Tumors
Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors
Establish safety and toxicity profile and preliminary response rate of CPI-0610 in MPNST patients and correlate response with pharmacodynamics markers and BET inhibition.
- Trial name
- NCT02986919
- Testing
- CPI-0610
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Cancer, End Stage Cancer
Information Needs Around Parenteral nUTrition in Cancer
This study will explore the information needs of patient's with advanced cancer, and their carers, when making a decision to commence or discontinue parenteral nutrition.
- Conditions
- Cancer, End Stage Cancer, Terminal Cancer, Neoplasms
- Trial name
- INPUT (NCT04495530)
- Testing
- Non-interventional study
- Where
- 4 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust